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Insomnia is common, persistent, and increases the risk for
relapse in alcohol-dependent (AD) patients. Abstinence has
long been considered the best strategy for allowing sleep to
normalize, although how many and which patients respond
to abstinence is unknown. The aims of this study were to in-
vestigate the prevalence and correlates of both baseline and
persistent insomnia in AD patients. The course of sleep prob-
lems in response to abstinence, moderate drinking, or relapse
following treatment was also examined. A naturalistic longi-
tudinal outcomes study interviewed 267 patients (69% male;
mean age of 44 years) with DSM-IV alcohol dependence at
baseline and 6 months later (84% follow-up rate). The Sleep
Problems Questionnaire, Time-Line Follow-Back Interview,
and Brief Symptom Inventory measured insomnia, drinking,
and psychiatric symptoms, respectively. Simple correlations,
logistic regression, and repeated measures analysis of vari-
ance were used to analyze the data. At baseline, 47% of pa-
tients were classified with insomnia, which was independently
predicted by female gender and psychiatric severity. Both ab-
stinence and moderate drinking outcomes significantly pre-
dicted a reduction of insomnia symptoms after controlling for
gender and psychiatric severity. Among patients with baseline
insomnia, however, insomnia persisted in over 60% of cases,
which was predicted by baseline insomnia severity. More-
over, insomnia persisted in one-quarter of patients despite
abstinence. Treatment aimed at preventing relapse to heavy
drinking provides good first-line therapy for insomnia in AD
patients, but some may require insomnia-specific evaluation
and treatment in addition to substance-focused treatment and
psychiatric care. (Am J Addict 2011;20:435-440)
INTRODUCTION
Many patients entering treatment for alcohol and other
drug use disorders report problems sleeping that persist be-
Received July 19, 2010; revised September 7, 2010; accepted
September 15, 2010.
Address correspondence to Dr. Brower, Department of
Psychiatry and Addiction Research Center, University of Michi-
gan, 4250 Plymouth Rd., SPC 5740, Ann Arbor, MI 48109–2700.
E-mail: kbrower@umich.edu.
yond the initial phase of substance withdrawal.1,2 Insomnia
is also common in the general population3 and is frequently
comorbid with a variety of psychiatric and medical disor-
ders.2,4 As a symptom, insomnia refers to complaints of
trouble falling asleep and staying asleep, or feeling dissat-
isfied with sleep. As a DSM-IV disorder, insomnia symp-
toms must be accompanied by either significant distress
or impairments in daytime functioning in order to fulfill
diagnostic criteria.5 DSM-IV also specifies that insomnia
may either be a primary disorder or induced by substances,
medication, or a medical disorder. When treating alcohol-
dependent (AD) patients, addiction-specialized clinicians
commonly assume that their patients’ insomnia is substance
induced, although psychiatric disorders such as depression
and activating antidepressants such as bupropion are also
well-appreciated causes of insomnia in this population.
Management of insomnia in AD patients, of course, de-
pends on an assessment of etiology and perpetuating fac-
tors.3 Prevailing conventional wisdom in the addiction field
holds that abstinence from alcohol and other drugs of abuse
is necessary and often sufficient treatment for insomnia.
Few studies, however, provide data to inform clinicians re-
garding the course of insomnia after starting treatment for
alcohol dependence, and whether insomnia responds only
to abstinence or if it also may respond to a reduction in
drinking to moderate levels.
The purpose of this study was to examine the 6-month
course of insomnia in AD patients. Questions to be an-
swered included (1) How prevalent is insomnia when start-
ing treatment and what factors distinguish between patients
with and without insomnia? (2) For what proportion of
patients does insomnia at baseline persist when assessed
6 months later, and what factors distinguish patients with
and without persistent insomnia? (3) How does the course
of drinking influence the course of insomnia over a 6-month
period? In particular, what effect does abstinence, moderate
drinking, and heavy drinking have on insomnia outcomes?
(4) How often does insomnia persist despite achieving good
drinking outcomes?
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TABLE 1. Correlates of baseline insomnia
Baseline insomnia Total
Baseline study variables/patient characteristics Yes (n = 125) No (n = 142) (n = 267) χ2 or t †
Demographics
Age (years) 44.8(12.2) 44.1(12.9) 44.5(12.5) −.43
Gender (male/female, %)∗∗ 62.4/37.6 74.6/25.4 68.9/31.1 4.10
Race (white/other, %) 85.6/14.4 90.1/9.9 88.0/12.0 .90
Education (years) 14.3(2.3) 14.4(2.5) 14.3(2.4) .32
Marital status (n = 264)‡ 1.74
Never married (%) 23.6 26.2 25.0
Married/living together (%) 38.2 43.3 40.9
Separated/divorced (%) 38.2 30.5 34.1
Employed (%)∗ 49.6 62.0 56.2 3.65
Clinical
Last drink (days) 29.9(27.5) 33.8(26.5) 32.0(26.9) 1.16
PDA in past 90 days 59.0(30.0) 61.2(29.2) 60.2(29.5) .59
PHDD in past 90 days 32.0(28.5) 30.3(27.0) 31.1(27.7) −.50
DDD in past 90 days 10.3(9.2) 9.2(6.5) 9.7(7.9) −1.17
SIP score∗∗∗ 23.4(10.8) 19.4(11.3) 21.3(11.2) −2.97
Age of onset (years) 29.4(13.0) 29.1(11.4) 29.2(12.1) −.16
DSM-IV symptom count∗∗ 5.8(1.3) 5.4(1.4) 5.6(1.4) −2.17
Psychiatric symptoms (#)∗∗∗∗ 28.3(13.0) 19.6(12.2) 23.7(13.3) −5.62
Total SPQ Score∗∗∗∗ 14.0(4.2) 5.0(3.1) 9.2(5.8) −19.47
†χ 2 and t (df = 265) values for categorical and continuous variables, respectively.
‡Three patients were widowed and not included in analysis.
PDA = percent days abstinent; PHDD = percent heavy drinking days; DDD = drinks per drinking day; SIP = Short Inventory of Problems; SPQ =
Sleep Problems Questionnaire. ∗p < .10; ∗∗p < .05; ∗∗∗p < .005; ∗∗∗∗p < .0005.
METHODS
A total of 364 volunteers who met DSM-IV criteria for
alcohol dependence were recruited to participate in a study
of spiritual change during recovery. Participation required
written informed consent and the study was approved by
the University of Michigan Institutional Review Board.
This study is a secondary analysis that excluded 93
individuals recruited from the community who were not
seeking treatment for their disorder, leaving 271 individuals
who were seeking help for their drinking. Four of them
were excluded because they had missing data regarding
their baseline sleep. Of the remaining 267 patients, 154
(57.7%), 80 (30.0%), and 33 (12.4%) were recruited from a
university hospital clinic, Veterans Administration clinic,
and moderation drinking program, respectively. Baseline
insomnia and follow-up rates did not differ by recruitment
site. Overall, follow-up assessments at 6 months were
conducted with 228 (85.4%) patients, of which 3 patients
had incomplete 6-month sleep data. Therefore, baseline
data pertain to 267 patients and 6-month data pertain to
225 (84.3%) patients. Table 1 shows baseline demographic
and clinical characteristics for the sample.
MEASURES
The diagnosis of alcohol dependence was confirmed
at baseline using the Structured Clinical Interview for
DSM-IV Diagnoses (SCID).6 Symptoms of insomnia were
assessed at both time points with the four-item, self-
administered Sleep Problems Questionnaire (SPQ), char-
acterized by scores ranging from 0 to 20 with higher scores
indicating greater sleep disturbance.7 The items ask about
trouble falling asleep, trouble staying asleep, waking too
early, and awakening in the morning feeling tired and worn
out. Patients rate each item on a scale of 0–5, based on
the number of days a symptom was experienced, with four
representing 15–21 days and five representing 22–31 days
in the past month, respectively. Because no cut-off score
for the SPQ is available, patients were classified as having
insomnia if they rated any one item as a four or five. This
method of classification was designed to reflect a common
convention that clinically significant insomnia occurs at
least 3 days weekly for at least 1 month.8–10
The Brief Symptom Inventory (BSI) is a 53-item self-
administered scale that measures psychiatric distress.11
Each item represents one symptom and is rated on
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0–4 Likert scale. The BSI has six subscales and three global
scales that are highly correlated with one another. Of par-
ticular interest for this study were symptoms of depres-
sion and anxiety, which are associated in the literature
with insomnia.12,13 Because the BSI anxiety and depression
subscales were highly correlated in this sample at baseline
(r = .73, p < .0005), one of the global BSI scales was se-
lected to represent them, thereby reducing the number of
comparisons and preventing the entry of highly correlated
measures into regression analyses. The Positive Symptom
Total scale is a numerical count of items endorsed (range
0–53), and correlated strongly with both the depression
(r = .77, p < .0005) and anxiety (r = .82, p < .0005) sub-
scales in this sample. It also has the advantage of simple
scoring and interpretation. Thus, it was used to measure
psychiatric severity.
The Time-Line Follow-Back Interview was used to mea-
sure drinking in the 90 days prior to baseline as well as
90 days prior to the 6-month follow-up assessment.14,15
Derived variables at baseline included percent days absti-
nent (PDA), percent heavy drinking days (PHDD), drinks
per drinking day (DDD), and time since last drink. De-
rived variables at the 6-month follow-up assessment in-
cluded three mutually exclusive categories: no drinking
(abstinence), moderate drinking, and any heavy drinking
(relapse). Moderate drinking was defined as no more than
three standard drinks in any 1 day for women, and no
more than four standard drinks in any 1 day for men. Pa-
tients who exceeded these limits were defined as having
relapsed to heavy drinking (four or more drinks in a day
for women and five or more drinks in a day for men). The
category of moderate drinking was included to examine the
response of insomnia to achieving that status, because one
of the programs was designed to facilitate that treatment
goal.
The Short Inventory of Problems is a 15-item self-
administered measure of alcohol-related problems in the
previous month.16 It was included to characterize alcohol
problem severity and to examine if insomnia was potentially
related to concerns about adverse consequences. In addi-
tion, a count of DSM-IV symptoms was derived from the
SCID and included as a measure of dependence severity to
determine if it correlated with insomnia.
Analyses
Descriptive statistics for continuous variables are
expressed as means and standard deviations (SDs), and
categorical variables are expressed as frequencies and/or
percentages. The baseline sample was next divided into
patients with and without baseline insomnia, and com-
pared on demographic and clinical characteristics using
chi-square tests for categorical variables and independent
samples t-tests for continuous variables, respectively.
Variables that differentiated groups at a level of p < .10,
with the exception of total SPQ scores, were then entered
simultaneously into a logistic regression analysis using a
forced entry method to determine the best predictors of
baseline insomnia. In this method, all selected variables are
entered as one block and forced to stay in the analysis, such
that the predictive significance of each variable is assessed
while controlling for all other variables in the model. For
follow-up analyses, the proportion of patients with per-
sistent insomnia was calculated, defined as meeting study
criteria for insomnia at both baseline and follow-up. To de-
termine the correlates of persistent insomnia, patients with
persistent insomnia were compared to patients with insom-
nia at baseline only, using the same procedures described
above for comparing patients with and without baseline
insomnia. In addition, baseline SPQ scores were compared
between those with and without persistent insomnia. To
examine the effect of drinking status (no, moderate, or
heavy drinking) in the 90 days prior to follow-up on the
course of insomnia from baseline to follow-up, a repeated
measures analysis of variance (ANOVA) was run using
total SPQ scores at baseline and follow-up as the repeated
measure and drinking group as the between subjects factor.
Significant correlates of baseline and follow-up insomnia
were entered in the ANOVA as covariates. Where appropri-
ate, an odds ratio (OR) with a 95% confidence interval (CI)
is specified. All analyses were performed with SPSS 17.0.
RESULTS
At baseline, 125 (46.8%) of 267 patients met study cri-
teria for insomnia. Baseline correlates of insomnia were fe-
male gender, alcohol problem severity (SIP score), DSM-IV
dependence symptom count, psychiatric symptom count,
and unemployment (Table 1). Variables not associated with
baseline insomnia were age, race, marital status, education,
and all drinking-related variables. When positive correlates
(p < .10) were entered simultaneously into a logistic re-
gression analysis, gender (OR = 2.38, 95% CI 1.34–4.23,
p = .003) and psychiatric severity (OR = 1.05, 95% CI:
1.03–1.08, p < .0005) remained as significant predictors of
baseline insomnia. Thus, women were more than twice as
likely as men to have baseline insomnia, and each addi-
tional psychiatric symptom increased the odds of insomnia
by 5%. The overall logistic regression model was significant
(χ2 = 40.97, df = 5, p < .0005) and explained 19.0% of the
variance (Nagelkerke R2) in baseline insomnia.
At the 6-month follow-up (n = 225), 107 (47.6%) pa-
tients were abstinent in the previous 90 days, 29 (12.9%)
were drinking moderately, and 89 (39.6%) had relapsed to
heavy drinking. Results of the repeated measures ANOVA
are shown in Fig. 1. A significant time by group interac-
tion was found. Post hoc analyses revealed that total SPQ
scores decreased (improved) significantly in abstinent and
moderate drinking patients (paired samples t = 3.97, df =
135, p < .0005), whereas no significant change over time
occurred in patients who relapsed to heavy drinking.


















FIGURE 1. A depiction of change in total scores on the Sleep
Problems Questionnaire (SPQ) from baseline to 6 months as a
function of drinking status at 6 months. A significant interaction
between time and drinking group is shown by parallel decreases
in scores (improvement in sleep) among patients achieving absti-
nence (n = 107) or drinking moderately (n = 29), whereas patients
who relapsed to heavy drinking (n = 89) show no improvement in
sleep (F = 5.71, df = 2,220, p = .004). Groups did not differ sig-
nificantly in baseline sleep scores.
Among the 225 followed patients, 103 (45.8%) had
insomnia at baseline and 64 of those (62.1%) had persistent
insomnia. Patients with (n = 64) and without (n = 39)
persistent insomnia were compared to look for baseline
predictors of persistent insomnia. Only baseline SPQ
scores and DSM-IV symptom count differed significantly
(p < .05) between groups. Those with persistent insomnia
had significantly higher SPQ scores (mean 14.6 [4.1]) than
those without (mean 12.1 [4.2], p = .003), and significantly
higher DSM-IV symptom counts (mean 6.0 [1.3]) than
those without (mean 5.3 [1.3], p = .009). In addition, the
mean (SD) Positive Symptom Total Scores for those with
and without persistent insomnia were 31.0 (12.8) versus
26.0 (11.3), respectively (t = 1.99, df = 101, p = .05); and
the mean (SD) SIP scores were 24.2 (10.9) and 20.3 (10.6),
respectively (t = 1.84, df = 101, p = .07). When these four
variables were entered into the logistic regression analysis,
the overall model was significant (χ = 15.39, df = 4, p =
.004) and predicted 18.9% of the variance (Nagelkerke R2)
in persistent insomnia. However, only baseline SPQ scores
significantly predicted persistent insomnia (OR = 1.16,
95% CI 1.04–1.30, p = .007). Thus, for every one point
increase in baseline SPQ score, participants were 1.16 times
more likely to report persistent insomnia at 6 months. In
other words, the 2.5-point difference in baseline mean SPQ
scores between those with and without persistent insomnia
translated into a 40% increase in odds.
Of the 64 patients with persistent insomnia, 26 (40.6%)
achieved abstinence, 8 (12.5%) were drinking moder-
ately, and 30 (46.9%) had relapsed to heavy drinking.
Thus, 34 (53.1%) of 64 patients with persistent insom-
nia had achieved good drinking outcomes, meaning they
did not relapse to heavy drinking. Of the 103 patients
with baseline insomnia, 26 (25.2%) and 8 (7.8%) had
persistent insomnia despite achieving abstinence and re-
ducing drinking to moderate levels, respectively. In other
words, 34 (33%) of the 103 patients with baseline insomnia
had persistent insomnia despite achieving good drinking
outcomes.
DISCUSSION
The main findings of this study were (1) about one-half
of patients near the time of treatment entry had symptoms
of insomnia that occurred at least 15 days or more in the
preceding month; (2) these insomnia symptoms were in-
dependently associated with female gender and psychiatric
symptom severity, but not alcohol-related variables; (3) in-
somnia symptoms improved significantly over 6 months
time with either abstinence or reduction in drinking to mod-
erate levels, whereas symptoms did not improve among pa-
tients who relapsed to heavy drinking; (4) insomnia symp-
toms also failed to improve in one-third of patients with
baseline insomnia (ie, one-half of patients with persistent
insomnia) despite abstinence or moderate drinking levels,
indicating that good drinking outcomes do not necessar-
ily always ensure improvement in sleep; and (5) persisting
insomnia was associated only with baseline insomnia, but
not with baseline psychiatric severity, gender, or severity of
dependence.
The prevalence of insomnia in this sample is consistent
with other studies, which have reported rates ranging from
36% to 91%,17,18 with an average rate across studies of 58%.
As with this study, these other studies were based on clini-
cal convenience samples. In a general population study, by
contrast, insomnia was reported by 28.4% of AD individu-
als, compared to an overall rate of 18.5%.19 In the general
population, insomnia is also more common in women than
men,13,20 which most likely explains the gender difference
found at baseline in this study.
A bivariate association between severity of dependence
and insomnia has been reported previously,21 although
the association in this study was not significant in the
multivariate analysis. Cohn et al.18 also did not find an
association between severity of dependence and sleep dis-
turbance. Other studies have found an association between
alcohol consumption variables and insomnia,22,23 although
this study did not. The absence of an association between
alcohol consumption and insomnia at baseline seems
inconsistent with the finding that insomnia improved with
both abstinence and reduction in drinking to moderate
levels. Several overlapping possibilities may explain these
discrepancies. First, insomnia can precede the development
of alcohol-related problems,24,25 which might explain why
its severity at baseline was independent of drinking pa-
rameters. Unless drinking was contributing to insomnia at
least in part, however, improvement with reduced drinking
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as occurred in this study would seem unlikely. Nevertheless,
the persistence of insomnia found in some cases despite
reduction in drinking would be expected with premorbid
insomnia. Second, insomnia may have been caused in large
part by comorbid factors such as psychiatric severity, and
improvement in sleep with reduced drinking under these
conditions would vary in accordance with the degree of
persisting psychiatric symptoms. A third explanation is
that alcohol consumption does contribute substantially to
insomnia, but not beyond a threshold level of consumption,
which treatment-seeking patients have already surpassed.
When drinking is reduced, therefore, the alcohol-related
“portion” of insomnia would significantly improve, but
other factors would better explain the variation in baseline
severity as well as its persistence in some cases.
The seemingly high level of persistent insomnia in over
60% of patients is confounded by relapse to heavy drink-
ing in about half of them. Nevertheless, the other half of
patients had persistent insomnia despite achieving either
abstinence (25%) or moderate drinking levels (8%). This is
important information for clinicians, because such patients
may require additional diagnostic assessment and special-
ized treatment approaches for either insomnia or other co-
morbid conditions.
The parallel improvement in insomnia with either absti-
nence or moderate drinking levels has key clinical impli-
cations. First, most patients who have insomnia associated
with alcohol dependence (ie, about two-thirds) will have sig-
nificant improvement of their sleep and remission of their
insomnia after either abstaining from drinking or reduc-
ing their drinking to moderate levels for a 3-month period.
Thus, treatment to eliminate heavy drinking remains the
single most important intervention for treating insomnia
in AD patients. Second, about one-fourth of patients will
have persistent insomnia despite achieving complete absti-
nence. These patients should have a detailed assessment for
insomnia, because factors other than drinking are likely to
be causing and maintaining it. Third, patients who achieve
moderate levels of drinking have the same degree of sleep
improvement as those that who achieve complete absti-
nence. Thus, insomnia that persists despite moderate levels
of drinking should be approached in the same manner as
insomnia that persists despite abstinence. In other words,
detailed assessment and treatment of insomnia for patients
who have sustained moderate drinking levels should not be
delayed until they achieve complete abstinence. Although
recommending abstinence is certainly preferable for most
AD patients, the findings of this study suggest that fur-
ther improvement in insomnia is unlikely to result once
moderate drinking is stable. Fourth, patients with persis-
tent insomnia who continue to drink heavily may belong
to a previously described group at risk for relapse because
of their insomnia.21,26,27 For these patients, symptomatic
treatment of insomnia28,29 while simultaneously intensi-
fying treatment for alcohol dependence may be the best
course of action.
This study has several limitations. Like other studies
of its kind, it is based on a convenience sample and may
not generalize to the full spectrum of alcohol use disor-
ders. Second, drinking outcomes were based on self-report
without collateral or biochemical corroboration, although
differences in self-report between those with and without
insomnia would not be expected. Drinking outcomes were
also limited to the 90 days prior to the 6-month follow-
up interval; however, those 90 days might be expected
to correlate most strongly with insomnia in the 1 month
prior to follow-up. Third, insomnia as defined in this study
does not fully capture insomnia as defined by DSM-IV,
which requires either significant distress about insomnia
or diminished daytime function resulting from insomnia,
in addition to symptoms about sleep quality. Fourth, in-
formation about psychiatric severity, while important, did
not extend to assessing co-occurring psychiatric disorders
such as major depression and nicotine dependence that are
strongly associated with both insomnia and alcohol de-
pendence. Similarly, information about medical conditions
or medications that might contribute to insomnia was not
obtained. Fifth, details of treatment received including its
duration, frequency of visits, and use of medications for
alcohol dependence, insomnia, and psychiatric disorders
were not analyzed. These last two limitations are particu-
larly crucial, rendering the results difficult to compare with
other studies and other clinical populations. Thus, caution
is advised when interpreting these results and applying them
to clinical settings.
Limitations such as these stem in part from analyzing
data from a study designed to study spiritual factors in re-
covery, not sleep. Nevertheless, the study also has several
strengths, including a reasonable sample size, multisite re-
cruitment, and inclusion of moderate drinking as a drinking
outcome. Future studies should include more frequent as-
sessment of insomnia symptoms during the first 6 months
to better describe how quickly symptoms remit, as well as
more detailed information on comorbid disorders and their
treatment.
In summary, nearly one-half of AD patients reported
frequent symptoms of insomnia in the month prior to seek-
ing treatment, especially women and those with concurrent
psychiatric symptoms. Most patients who achieved absti-
nence or reduced their drinking to moderate levels had sig-
nificantly improved sleep when measured 6 months later,
while sleep did not improve among those who relapsed to
heavy drinking. Among those with baseline insomnia, how-
ever, sleep problems persisted in about one-third of them
despite good drinking outcomes. Such patients are candi-
dates for further diagnostic assessment and consideration
for insomnia-specific treatment.
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